Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial"
- PMID: 31714312
- DOI: 10.1097/SLA.0000000000003679
Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial"
Conflict of interest statement
The authors report no conflicts of interest.
Comment in
-
Response to the Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial".Ann Surg. 2021 Aug 1;274(2):e195-e196. doi: 10.1097/SLA.0000000000003676. Ann Surg. 2021. PMID: 31714317 No abstract available.
Comment on
-
Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial.Ann Surg. 2019 Jun;269(6):1025-1033. doi: 10.1097/SLA.0000000000003062. Ann Surg. 2019. PMID: 31082898 Clinical Trial.
References
-
- Troisi RI, Vanlander A, Giglio MC, et al. Somatostatin as inflow modulator in liver-transplant recipients with severe portal hypertension. Ann Surg 2019; 269:1025–1033.
-
- Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50:923–928.
-
- Silva-Junior G, Turon F, Baiges A, et al. Timing affects measurement of portal pressure gradient after placement of transjugular intrahepatic portosystemic shunts in patients with portal hypertension. Gastroenterology 2017; 152:1358–1365.
-
- Steinlauf AF, Garcia-Tsao G, Zakko MF, et al. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. Hepatology 1999; 29:1070–1073.
-
- Reverter E, Blasi A, Abraldes JG, et al. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int 2014; 34:16–25.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources